Neuropathological abnormalities of astrocytes, GABAergic neurons, and pyramidal neurons in the dorsolateral prefrontal cortices of patients with major depressive disorder

European Neuropsychopharmacology

Volumn 22, Issue 5, 2012, Pages 330-338

  Oh, Dong Hoon ^a   Son, Hyeon ^a   Hwang, Sejin ^a   Kim, Seok Hyeon ^a  

^a Hanyang University   (South Korea)

Author keywords

Calretinin; Data mining; Dorsolateral prefrontal cortex; Glutamate; Major depressive disorder

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; CALRETININ; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMIC ACID;

ARTICLE; ASTROCYTE; CONTROLLED STUDY; DATA BASE; EXCITOTOXICITY; FEMALE; GLIA CELL; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; NEUROPATHOLOGY; NEUROTRANSMISSION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL;

ASTROCYTES; DATABASES, FACTUAL; DEPRESSIVE DISORDER, MAJOR; GABAERGIC NEURONS; HUMANS; PREFRONTAL CORTEX; PYRAMIDAL CELLS;

EID: 84859210825     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.09.001     Document Type: Article

References (40)

1. Alcaro A., Panksepp J., Witczak J., Hayes D.J., Northoff G. Is subcortical-cortical midline activity in depression mediated by glutamate and GABA? A cross-species translational approach. Neurosci. Biobehav. Rev. 2010, 34:592-605.
2. Banasr M., Chowdhury G.M., Terwilliger R., Newton S.S., Duman R.S., Behar K.L., Sanacora G. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol. Psychiatry 2010, 15:501-511.
3. Beasley C.L., Zhang Z.J., Patten I., Reynolds G.P. Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol. Psychiatry 2002, 52:708-715.
4. Choudary P.V., Molnar M., Evans S.J., Tomita H., Li J.Z., Vawter M.P., Myers R.M., Bunney W.E., Akil H., Watson S.J., Jones E.G. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:15653-15658.
5. Cotter D., Mackay D., Chana G., Beasley C., Landau S., Everall I.P. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb. Cortex 2002, 12:386-394.
6. Cotter D., Mackay D., Frangou S., Hudson L., Landau S. Cell density and cortical thickness in Heschl's gyrus in schizophrenia, major depression and bipolar disorder. Br. J. Psychiatry 2004, 185:258-259.
7. Davidson R.J., Putnam K.M., Larson C.L. Dysfunction in the neural circuitry of emotion regulation-a possible prelude to violence. Science 2000, 289:591-594.
8. DeFelipe J. Types of neurons, synaptic connections and chemical characteristics of cells immunoreactive for calbindin-D28K, parvalbumin and calretinin in the neocortex. J. Chem. Neuroanat. 1997, 14:1-19.
9. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 2007, 62:1310-1316.
10. Hasler G., Neumeister A., van der Veen J.W., Tumonis T., Bain E.E., Shen J., Drevets W.C., Charney D.S. Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy. Biol. Psychiatry 2005, 58:969-973.
11. Hasler G., van der Veen J.W., Tumonis T., Meyers N., Shen J., Drevets W.C. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 2007, 64:193-200.
12. Karolewicz B., Maciag D., O'Dwyer G., Stockmeier C.A., Feyissa A.M., Rajkowska G. Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression. Int. J. Neuropsychopharmacol. 2010, 13:411-420.
13. Kim S., Webster M.J. Correlation analysis between genome-wide expression profiles and cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders. Mol. Psychiatry 2010, 15:326-336.
14. Kim S., Webster M.J. The Stanley neuropathology consortium integrative database: a novel, web-based tool for exploring neuropathological markers in psychiatric disorders and the biological processes associated with abnormalities of those markers. Neuropsychopharmacology 2010, 35:473-482.
15. Koenigs M., Grafman J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav. Brain Res. 2009, 201:239-243.
16. Law A.J., Harrison P.J. The distribution and morphology of prefrontal cortex pyramidal neurons identified using anti-neurofilament antibodies SMI32, N200 and FNP7. Normative data and a comparison in subjects with schizophrenia, bipolar disorder or major depression. J. Psychiatr. Res. 2003, 37:487-499.
17. Lee J.S., Jang D.J., Lee N., Ko H.G., Kim H., Kim Y.S., Kim B., Son J., Kim S.H., Chung H., Lee M.Y., Kim W.R., Sun W., Zhuo M., Abel T., Kaang B.K., Son H. Induction of neuronal vascular endothelial growth factor expression by cAMP in the dentate gyrus of the hippocampus is required for antidepressant-like behaviors. J. Neurosci. 2009, 29:8493-8505.
18. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., Manji H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 2008, 63:349-352.
19. Miguel-Hidalgo J.J., Baucom C., Dilley G., Overholser J.C., Meltzer H.Y., Stockmeier C.A., Rajkowska G. Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol. Psychiatry 2000, 48:861-873.
20. Milham M.P., Banich M.T., Webb A., Barad V., Cohen N.J., Wszalek T., Kramer A.F. The relative involvement of anterior cingulate and prefrontal cortex in attentional control depends on nature of conflict. Brain Res. Cogn. Brain Res. 2001, 12:467-473.
21. Mineur Y.S., Picciotto M.R., Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol. Psychiatry 2007, 61:250-252.
22. Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol. Psychiatry 2002, 51:775-787.
23. Mueller H.T., Meador-Woodruff J.H. NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder. Schizophr. Res. 2004, 71:361-370.
24. Oh D.H., Park S.C., Park Y.C., Kim S.H. Excessive activation of the loop between the NR2B subunit of the NMDA receptor and GSK-3β in the hippocampi of patients with major depressive disorder 2011, Acta Neuropsychiatr, [Electronic publication ahead of print].
25. Petroff O.A. GABA and glutamate in the human brain. Neuroscientist 2002, 8:562-573.
26. Rajkowska G., Miguel-Hidalgo J.J. Gliogenesis and glial pathology in depression. CNS Neurol. Disord. Drug Targets 2007, 6:219-233.
27. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., Overholser J.C., Roth B.L., Stockmeier C.A. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol. Psychiatry 1999, 45:1085-1098.
28. Rajkowska G., O'Dwyer G., Teleki Z., Stockmeier C.A., Miguel-Hidalgo J.J. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology 2007, 32:471-482.
29. Reynolds G.P., Beasley C.L., Zhang Z.J. Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons. J. Neural. Transm. 2002, 109:881-889.
30. Rogers M.A., Kasai K., Koji M., Fukuda R., Iwanami A., Nakagome K., Fukuda M., Kato N. Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neurosci. Res. 2004, 50:1-11.
31. Sanacora G., Saricicek A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol. Disord. Drug Targets 2007, 6:127-140.
32. Sanacora G., Mason G.F., Rothman D.L., Behar K.L., Hyder F., Petroff O.A., Berman R.M., Charney D.S., Krystal J.H. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 1999, 56:1043-1047.
33. Sanacora G., Gueorguieva R., Epperson C.N., Wu Y.T., Appel M., Rothman D.L., Krystal J.H., Mason G.F. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry 2004, 61:705-713.
34. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 2008, 7:426-437.
35. Si X., Miguel-Hidalgo J.J., O'Dwyer G., Stockmeier C.A., Rajkowska G. Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology 2004, 29:2088-2096.
36. Thomas A.J., Davis S., Ferrier I.N., Kalaria R.N., O'Brien J.T. Elevation of cell adhesion molecule immunoreactivity in the anterior cingulate cortex in bipolar disorder. Biol. Psychiatry 2004, 55:652-655.
37. Tokita K., Yamaji T., Hashimoto K. Roles of glutamate signaling in preclinical and/or mechanistic models of depression 2011, Pharmacol. Biochem, Behav, [Electronic publication ahead of print].
38. Torrey E.F., Webster M., Knable M., Johnston N., Yolken R.H. The Stanley foundation brain collection and neuropathology consortium. Schizophr. Res. 2000, 44:151-155.
39. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., Rachmanova V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 2004, 67:269-275.
40. Warner-Schmidt J.L., Duman R.S. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:4647-4652.